28 results
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
8:01am
and older Dosage and Administration All healthcare professionals should receive instructions and training prior to preparation and administration
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
27 Jul 23
Regulation FD Disclosure
4:15pm
and pediatric patients 2 years of age and older Dosage and Administration All healthcare professionals should receive instructions and training prior
8-K
EX-99.2
VRCA
Verrica Pharmaceuticals Inc
24 Jul 23
Regulation FD Disclosure
7:31am
instructions and training prior to preparation and administration of YCANTH For topical use only. Not for Oral, mucosal, or ophthalmic use Apply a single
8-K
EX-99.1
s8t4uq r6
10 Aug 21
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:01am
8-K
EX-99.1
yata1qq s72z9
28 May 21
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
7:58am
8-K
0ev061e78f6
23 Jul 20
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
7:45am
8-K
EX-99.1
b795y
17 Apr 20
Regulation FD Disclosure
8:01am
8-K
EX-99.2
dnaw 6xuvrh35k
18 Oct 19
Verrica Pharmaceuticals Announces Presentation of Positive Data
7:08am
DEF 14A
i8jas 51j
25 Apr 19
Definitive proxy
8:51am
10-K
nnksfyve6xsmhpl7a
7 Mar 19
Annual report
4:26pm